JP5972367B2 - 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体 - Google Patents

神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体 Download PDF

Info

Publication number
JP5972367B2
JP5972367B2 JP2014517749A JP2014517749A JP5972367B2 JP 5972367 B2 JP5972367 B2 JP 5972367B2 JP 2014517749 A JP2014517749 A JP 2014517749A JP 2014517749 A JP2014517749 A JP 2014517749A JP 5972367 B2 JP5972367 B2 JP 5972367B2
Authority
JP
Japan
Prior art keywords
phenyl
thiadiazol
piperazine
ethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014517749A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518240A (ja
JP2014518240A5 (https=
Inventor
グリフィオン，ジェラルド
ネッテコーフェン，マティアス
プリンセン，カトリーン
ラトニ，ハサネ
ビフィアン，ウォルター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
reMYND NV
Original Assignee
reMYND NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by reMYND NV filed Critical reMYND NV
Publication of JP2014518240A publication Critical patent/JP2014518240A/ja
Publication of JP2014518240A5 publication Critical patent/JP2014518240A5/ja
Application granted granted Critical
Publication of JP5972367B2 publication Critical patent/JP5972367B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2014517749A 2011-07-01 2012-06-29 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体 Expired - Fee Related JP5972367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11172324.3 2011-07-01
EP11172324 2011-07-01
PCT/EP2012/062778 WO2013004642A1 (en) 2011-07-01 2012-06-29 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2014518240A JP2014518240A (ja) 2014-07-28
JP2014518240A5 JP2014518240A5 (https=) 2015-05-28
JP5972367B2 true JP5972367B2 (ja) 2016-08-17

Family

ID=46545347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517749A Expired - Fee Related JP5972367B2 (ja) 2011-07-01 2012-06-29 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体

Country Status (9)

Country Link
US (1) US9023852B2 (https=)
EP (1) EP2726470B1 (https=)
JP (1) JP5972367B2 (https=)
CN (1) CN103619825B (https=)
AU (1) AU2012280420B2 (https=)
CA (1) CA2837247C (https=)
ES (1) ES2540956T3 (https=)
PL (1) PL2726470T3 (https=)
WO (1) WO2013004642A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2744798T3 (pl) 2011-08-17 2016-08-31 Remynd Nv Pochodne tiazolu piperazyny użyteczne w leczeniu tauopatii, takich jak choroba alzheimera
WO2015140130A1 (en) * 2014-03-17 2015-09-24 Remynd Nv Oxadiazole compounds
AU2017281907B2 (en) * 2016-06-23 2021-10-21 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR102728619B1 (ko) 2017-12-27 2024-11-08 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
EP3731859B1 (en) 2017-12-27 2025-08-20 St. Jude Children's Research Hospital, Inc. Pyridazine compounds for use to treat disorders associated with castor
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2025104092A1 (en) 2023-11-13 2025-05-22 Remynd N.V. Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1161424E (pt) * 1999-03-03 2004-08-31 Wyeth Corp Novos derivados de diazole como agentes serotonergicos
CA2367695A1 (en) * 1999-04-26 2000-11-02 Neurosearch A/S Heteroaryl diazacycloalkanes, their preparation and use
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
PE20070099A1 (es) * 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2007092435A2 (en) * 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases

Also Published As

Publication number Publication date
US20140128404A1 (en) 2014-05-08
US9023852B2 (en) 2015-05-05
JP2014518240A (ja) 2014-07-28
PL2726470T3 (pl) 2015-09-30
HK1192726A1 (en) 2014-08-29
CN103619825A (zh) 2014-03-05
ES2540956T3 (es) 2015-07-15
CA2837247A1 (en) 2013-01-10
EP2726470B1 (en) 2015-04-29
AU2012280420A1 (en) 2013-12-12
CA2837247C (en) 2020-03-31
WO2013004642A1 (en) 2013-01-10
AU2012280420B2 (en) 2017-01-05
CN103619825B (zh) 2015-10-14
EP2726470A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
JP5972367B2 (ja) 神経変性疾患の治療に有用な１，２，４−チアジアゾール−５−イルピペラジン誘導体
EP1678171B1 (en) 2-amino-4-thiazolone-pyrimidine derivatives as protein kinase inhibitors
US7157476B2 (en) Aminofurazan compounds useful as protein kinase inhibitors
JP2008515992A (ja) 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
CA2533870A1 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
JP2007520540A (ja) 化合物
WO2005012262A1 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
CN113880809A (zh) 一种嘧啶类衍生物及其制备方法和应用
JP6051218B2 (ja) アルツハイマー病等のタウオパチーの治療に有用なピペラジンチアジアゾール誘導体
HK1192726B (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
CN1898237B (zh) 嘧啶-4-基-3,4-硫酮化合物及其治疗用途
HK40070301A (en) Pyrimidine derivative as well as preparation method and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160712

R150 Certificate of patent or registration of utility model

Ref document number: 5972367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees